세계의 보행동결 시장 예측(-2030년)

Market Overview

Freeze of Gait Market is projected exhibit a compound annual growth rate (CAGR) of 4.86% during the forecast period. The Rising transcendence of freeze of gait is one of the critical driving components for market advancement.

Parkinson's contamination is an issue of the central tactile framework that causes inadvertent or wild turns of events, like solidness, shaking, and issue with coordination and balance. These aftereffects generally begin steadily and annihilate once again the long run. This could achieve inconvenience walking and talking. Freezing of gait (Fog) is perhaps of the most debilitating motor aftereffect in Parkinson's affliction (PD) patients. Freezing of gait is a peculiar gait plan that prompts an unforeseen inability to begin or walk.

According to data appropriated in Nature Journal, in the year 2022, Fog affected around half of Parkinson's ailment patients and 80% of state-of-the-art Parkinson's disorder patients. According to the Parkinson's Foundation, at the present time around a million people in the US are living with Parkinson's disease (PD), and it is surveyed that this number will rise to 1.2 million by 2030.

Market Segmentation

Deep brain stimulation, wearable technology, walking aids, oral dopaminergic medications, and other products are included in the Freeze of Gait Market categorization based on type.

The Freeze of Gait Market is segmented according to end users, which encompasses clinics, hospitals, and other establishments.

Regional Insights

The North America Freeze of Gait market is supposed to represent USD 0.48 billion out of 2022 and is supposed to show a 5.17% CAGR during the review time frame. This is credited to the business presence of significant vital participant, rising FDA endorsement, and expanding mindfulness about the prescription and treatments, rising pervasiveness of Parkinson sickness in the region drive the regional market development during the forecast time frame.

Europe Freeze of Gait market is supposed to represent the second-biggest piece of the pie because of the rising medical care use, rising interest for cutting edge therapeutics, and expanding geriatric populace led to gamble of Parkinson illness related freeze of gait which drive the development of freeze gait in Europe region.

Openness to trend setting innovation for sickness finding, the rising geriatric populace inclined to Freeze of Gait is driving up interest for powerful therapy and therapeutics and expanding mindfulness about the freeze of gait.

The Asia-Pacific freeze of gait market is supposed to develop at a CAGR of 6.03% from 2023 to 2030. This is because of elements, for example, rising clinical office, expanding government drive for freeze gait treatment, presence of enormous patient pool of Parkinson illness related with freeze of gait are decidedly influence on the development of freeze of gait market in Asia-Pacific region. The Rest of the World incorporates the Middle East, Africa, and Latin America.

Market Overview

Key Companies in the Freeze of Gait Market Include Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), and Ustep (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF PARKINSON'S DISEASE AND OTHER RELATED DISEASES
  • 4.2.2 GROWING GERIATRIC POPULATION
  • 4.2.3 INCREASING INVESTMENT IN R&D
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY REQUIREMENTS
• 4.4 OPPORTUNITIES
  • 4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D AND DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION, MARKETING, AND SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET
  • 5.3.1 OVERVIEW
  • 5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS
  • 5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS
  • 5.3.4 IMPACT ON ELECTIVE PROCEDURE
  • 5.3.5 IMPACT ON SUPPLY CHAIN

6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 ORAL DOPAMINERGIC MEDICATION
• 6.3 WEARABLE AND WALKING AID DEVICES
• 6.4 DEEP BRAIN STIMULATION
• 6.5 OTHERS

7 GLOBAL FREEZE OF GAIT MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HOSPITALS
• 7.3 CLINICS
• 7.4 OTHERS

8 GLOBAL FREEZE OF GAIT MARKET, BY REGION

• 8.1 NORTH AMERICA
  • 8.1.1 US
  • 8.1.2 CANADA
• 8.2 EUROPE
  • 8.2.1 GERMANY
  • 8.2.2 FRANCE
  • 8.2.3 UK
  • 8.2.4 ITALY
  • 8.2.5 SPAIN
  • 8.2.6 REST OF EUROPE
• 8.3 ASIA-PACIFIC
  • 8.3.1 CHINA
  • 8.3.2 INDIA
  • 8.3.3 JAPAN
  • 8.3.4 AUSTRALIA
  • 8.3.5 SOUTH KOREA
  • 8.3.6 REST OF ASIA-PACIFIC
• 8.4 REST OF THE WORLD
  • 8.4.1 MIDDLE EAST
  • 8.4.2 AFRICA
  • 8.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET
• 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.5.1 PARTNERSHIP & COLLABORATIONS
• 9.6 MAJOR PLAYERS SALES ANALYSIS
  • 9.6.1 SALES & OPERATING INCOME
• 9.7 MAJOR PLAYERS R&D ANALYSIS

10 COMPANY PROFILES

• 10.1 VIATRIS INC.
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 GONDOLA MEDICAL TECHNOLOGIES SA
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 USTEP
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 GYENNO TECHNOLOGIES CO., LTD.
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 SWOT ANALYSIS
  • 10.4.6 KEY STRATEGIES
• 10.5 MEDEXO ROBOTICS
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 KEY STRATEGIES
• 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL ANALYSIS
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 SUN PHARMACEUTICAL INDUSTRIES LTD
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 WALK WITH PATH
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 BEATS MEDICAL LIMITED
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 AGILITAS
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS